Related Experiment Videos
Evaluation of beta 2-microglobulin removal with high-performance hemodiafiltration
E Kinugasa1, T Akizawa, T Kitaoka
1Department of Internal Medicine, Fujigaoka Hospital, Showa University, Yokohama, Japan.
Artificial Organs
|February 1, 1988
Summary
Dialysis-associated amyloidosis (DAA) stems from beta 2-microglobulin (beta 2M) buildup. Hemodiafiltration with high-performance membranes and hemodialysis with PAN membranes show promise for beta 2M removal in DAA patients.
Area of Science:
- Nephrology
- Biomedical Engineering
Background:
- Beta 2-microglobulin (beta 2M) accumulation is linked to dialysis-associated amyloidosis (DAA) in long-term hemodialysis patients.
- DAA manifests clinically as carpal tunnel syndrome, osteoarthropathy, and other organ damage.
Purpose of the Study:
- To evaluate the efficiency of beta 2M removal using various dialysis methods.
- To assess the potential of these methods in preventing beta 2M accumulation and managing DAA.
Main Methods:
- Compared beta 2M removal across hemodialysis (HD), hemofiltration (HF), charcoal hemoperfusion, and hemodiafiltration (HDF) using high-performance membranes (HPM).
- Evaluated 27 patients undergoing different treatment modalities.
- Assessed clinical symptom improvement and serum beta 2M levels over time.
Main Results:
- Significant beta 2M removal was observed with HDF using HPM and HD using polyacrylonitrile (PAN) membranes.
- HDF with HPM for over 6 months showed no significant clinical improvement in patients.
- Serum beta 2M levels decreased in only two of 15 patients treated with HDF with HPM.
Conclusions:
- HDF with HPM and HD with PAN membranes appear most effective for beta 2M removal.
- Long-term studies are required to determine if these procedures can be successful therapeutic regimens for DAA.